MiniMed launches Abbott-made Instinct blood glucose sensor in Europe, expanding CGM ecosystem

MiniMed Launches Abbott-Made Instinct Glucose Sensor in Europe

MiniMed announced on Tuesday that it has officially launched in the European market the Instinct continuous glucose monitoring (CGM) sensor, developed in collaboration with Abbott. The sensor received CE marking in March of this year, just days after MiniMed was spun off from Medtronic and listed independently.

The launch of the Instinct sensor marks a further deepening of MiniMed's strategy in diabetes management. The sensor integrates seamlessly with the MiniMed 780G insulin pump system, offering patients a wear time of up to 15 days, compared to MiniMed's own Simplera sensor, which only supports 7 days. This differentiated product portfolio is designed to meet the needs of different patients.

Industry Background

MiniMed's independent listing and its collaboration with Abbott reflect profound changes in the diabetes device market. Traditionally, there has been strong brand lock-in between CGM and insulin pumps, but in recent years, open protocols and interoperability have become trends. By offering both its self-developed Simplera and the Abbott-made Instinct, MiniMed retains its own ecosystem while embracing a broader user base.

Abbott's CGM products have a large global user base, with over 4.5 million patients receiving intensive insulin therapy using Abbott sensors in Europe alone. MiniMed CEO Que Dallara stated during this month's earnings call that the launch of Instinct in Europe will allow MiniMed to promote its 780G insulin pump to these users, thereby opening up previously inaccessible markets.

Key Progress

• CE Marking and Launch Timeline: Instinct received CE marking in March 2026, and MiniMed is rolling it out gradually in Europe starting this month.
• Product Features: Instinct is a 15-day disposable sensor, while Simplera is a 7-day sensor. Dallara noted that some patients prefer Simplera's 7-day cycle to align with infusion set changes, while others favor Instinct's longer wear time.
• Market Performance Reference: In the U.S. market, the launches of Instinct and Simplera drove a 18.2% year-over-year increase in MiniMed's CGM revenue for the second half of fiscal 2026, and also brought U.S. pump sales back to growth (8% growth in the third quarter).

Market ImpactMiniMed's international market revenue accounts for 70% of total revenue (fiscal year 2026), with international market sales growing 20.6% year-over-year, far exceeding the 1.5% growth in the U.S. market. The launch of Instinct in Europe is expected to further accelerate international growth. Dallara expects that with the launch of Instinct and the easing of Simplera supply constraints, key indicators for new pump sales in Europe will continue to rise.

For Abbott, its partnership with MiniMed solidifies its position as an open CGM platform provider, allowing its sensors to connect with more insulin pump systems. This "plug-and-play" model may drive interoperability standards across the diabetes device industry.

Challenges and Risks

• Intensified Competition: Competitors such as Dexcom are also advancing integration with pump systems, requiring MiniMed to continuously innovate to maintain its advantage.
• Profit Margin Differences: CFO Chad Spooner acknowledged during the earnings call that Simplera's gross margin is lower than Instinct's, but the company does not favor one over the other, allowing patients to choose based on lifestyle.
• Operational Independence Post-Spin-off: As an independent company, MiniMed must prove that its supply chain and R&D capabilities do not rely on Medtronic.

Future Outlook

MiniMed's strategic core is to expand its user base by offering multiple sensor options and to increase the penetration rate of the 780G pump. With European regulatory support for interoperability, more third-party sensors may be integrated into the MiniMed system in the future. Over the next 3-5 years, deep integration of CGM and insulin pumps is expected to become mainstream in diabetes management, and the collaboration model between MiniMed and Abbott may set a benchmark for the industry.

Conclusion

MiniMed's launch of the Instinct sensor in Europe is not only a critical step after its spin-off but also reflects the industry's shift from closed ecosystems to open interoperability. As more patients gain choices, the core of enterprise competition will transition from hardware lock-in to data services and user experience. The capital market's focus will be on whether MiniMed can replicate its U.S. growth curve in Europe and how other companies like Abbott will further expand collaboration boundaries.